Navigation Links
New Chemo Drug May Benefit Some Breast Cancer Patients
Date:3/2/2011

WEDNESDAY, March 2 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.

The researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.

The study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.

The most common side effects in both groups were fatigue and depletion of white blood cells. Numbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study (24, or 5 percent).

The study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin. Dr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.

"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit," the authors wrote.

In a related editorial, Drs. Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: "EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer. And that evidence suggests that the methods to treat advanced breast cancer are growing, the treatment challenge in refractory disease is a little bit less daunting, and the treatment results are a little bit better than they were before."

Commenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, "The findings of this trial are exciting because they will propel eribulin into wider use. This drug shows much promise, and it should certainly be included in additional trials to fully establish its benefit."

"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin," she added.

More information

The Metastatic Breast Cancer Network has more about metastatic breast cancer.

-- Robert Preidt

SOURCE: Stephanie Bernik, M.D., F.A.C.S., chief of surgical oncology at Lenox Hill Hospital, New York City, N.Y.; The Lancet, news release, March 2, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. BUSM study shows chemoradiotherapy prior to surgery improves survival
2. Fish oil fights weight loss due to chemotherapy
3. Pot Ingredient May Restore Appetite After Chemo
4. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
5. Stray Breast Tumor Cells in Early Chemo Could Be Bad Sign
6. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
7. Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
8. Surgery complications linked to chemotherapy delay, U-M study finds
9. Breast cancer: Reducing the risk of unnecessary chemo
10. Combining radiation therapy, chemotherapy safely treats head and neck cancer patients
11. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Chemo Drug May Benefit Some Breast Cancer Patients
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a multi-modal ... end-to-end supply chain management firm with expertise serving clients ... Solutions Rick Zaffarano was named a 2017 ... Supply Chain by the only publication exclusively dedicated to ... supply chain. "Rick has brought to Transportation ...
Breaking Medicine Technology: